The Centre for Personalised Medicine has officially launched at Canberra Hospital, aiming to utilize cutting-edge technology for the treatment of individuals with intricate immune disorders.
Simon Jiang, the centre’s director, emphasized that the facility’s methodology focuses on pinpointing the underlying causes of diseases, rather than merely alleviating symptoms.
The centre will be open to referrals from all over Australia.
Emma Gilmour recounts the remarkable transformation her late father, Arthur, experienced following a sophisticated immune therapy. “He transitioned from being confined to a wheelchair and spending seven consecutive months in the hospital nearly a decade ago to essentially running around and getting into mischief, like climbing ladders,” she shared.
Ms. Gilmour noted that her father had been significantly ill from an early age, suffering strokes in his early 40s. By 2017, the same year he was referred to Associate Professor Simon Jiang at the Australian National University’s John Curtin School of Medical Research, Arthur Hodge had endured two decades of severe pain and was under palliative care.
“Twenty-five years ago, we were first told to say our goodbyes to Dad,” Ms. Gilmour recalled.
She explained that multiple healthcare providers had attempted to diagnose and treat him but to no avail. “He had numerous clinicians trying different approaches, leading to a cocktail of medications,” she stated.
However, Associate Professor Jiang’s innovative method, which targets the genetic and immunological factors contributing to a patient’s immune condition, marked a significant turning point. “What Simon accomplished for Dad in the past decade gave us an additional 10 years with him,” Ms. Gilmour remarked.
The new Centre for Personalised Medicine at Canberra Hospital opened its doors today, providing similar treatment options to Australians with complex immune issues for the very first time.
Rachel Stephen-Smith, the ACT Health Minister, noted that the centre aims to merge cutting-edge scientific research with bedside treatment. “This centre will accept referrals from across the nation to undertake initiatives that no other facility has yet established,” Ms. Stephen-Smith explained.
The establishment is financially supported by the federal government through the National Health Medical Research Council, the Medical Research Future Fund, the Australian National University, Canberra Health Services, and various philanthropic contributors. “This initiative represents a true collaboration between Canberra Health Services, ANU, philanthropic supporters, and Commonwealth research institutions,” she added.
The centre will also collaborate with the National Centre for Indigenous Genomics to explore new treatment avenues for kidney diseases affecting Aboriginal and Torres Strait Islander populations.
Marilyn Hines, who received a diagnosis of antisynthetase syndrome in 2023, discovered Simon Jiang’s work about a year later. “I was fortunate to be referred to Simon, especially since it’s such a rare condition,” Ms. Hines said. “Simon delves into the essence of the condition and understands its causes, tailoring medications that effectively target these issues.”
She reported an improvement in her quality of life and a reduction in her medication intake due to the personalized treatment. “It’s crucial to live a healthier life and engage in regular activities rather than spending extended periods in the hospital,” she remarked.
According to Associate Professor Jiang, a straightforward analogy for understanding their treatment approach is to visualize a hazardous intersection prone to accidents. While traditional methods might set up traffic signals after crashes occur, his approach involves examining each vehicle to ascertain the specific reasons for the collisions.
“We may discover a particular defect in one specific car that is responsible for the accidents. By addressing that issue, we can prevent further incidents,” he explained. This examination utilizes blood samples for personalized medicine assessments that include genomic analysis and immune cell evaluation.
Ms. Gilmour, along with her 18-year-old son, has learned that they share the same rare gene mutation that affected her father, Arthur Hodge. “Dad felt a sense of guilt because both my son and I tested positive. However, we viewed it as a blessing because it allowed us to seek assistance much earlier,” she said. “Thanks to Dad’s connection with Simon, I am 25 years ahead in my journey.”
